An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Eisai Clinical Trials

An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer’s Disease

Protocol # E2814-G000-103

Study Overview

Study Compound: E2814

Drug Name: E2814

Registry #: NCT04971733, 2020-005728-12

Trial Period: Jun 2021 - May 2024

Indication: Alzheimer's disease

Primary Endpoint: 1. Cohort A, Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) [Time Frame: Up to 20 weeks]

2. Cohort A, Phase 2 and Cohort B: Number of Participants With TEAEs [Time Frame: Up to 108 weeks]

Population
Males and females 18 Years to 80 Years (Adult, Older Adult)
Study Status
Completed
Study Phase
Phase 1 / 2
Countries
United Kingdom, United States See moreSee less

Results

CSR Synopsis

No download available

Lay Summary

Download PDF

Publication reference citation

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

CSDR Sharing is not available for this study.

CSDR	Availability
Clinical Trial Data

Redacted documents may be available upon request for this study.

Document type	Availability
Protocol
SAP
Sample CRF
Full CSR